Diana Abdueva, Aqtual CEO
October 31, 2023 12:01 AM EDTUpdated 01:35 AM
Financing

Aq­tu­al rais­es $16M for liq­uid biop­sy test for rheuma­toid arthri­tis based on cell-free DNA plat­form

Katherine Lewin

News Reporter

Aq­tu­al emerged from stealth on Tues­day with $16 mil­lion in Se­ries A funds and plans to use its cell-free DNA plat­form to de­vel­op a blood …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times